But recently, the subsequent phase II INDUCE-3 trial comparing feladilimab or placebo plus pembrolizumab among patients with PD-L1+ HNSCC was terminated for futility (36). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.